SFI Health™ EMEA Announces the Launch in Portugal of Equazen® Food Supplements, the Brand Developed to Support Cognitive Needs
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is excited to announce that Equazen® products will soon be available in Portugal. The company specializes in clinically researched products in microbiome, cognition, and well-being.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250226258206/en/
Discover Equazen®, a science-based food supplement designed and studied to help nourish, enhance, and support the human brain’s potential across all life stages. (Graphic: Business Wire)
This marks a significant step forward in SFI Health™ EMEA's ongoing European expansion, following the exclusive license-in agreement signed in February 2024 with Eqyon Healthcare Solutions, a local distributor specialized in healthcare products. Under the terms of the agreement, Eqyon will use its sales and marketing expertise to distribute Equazen® range in pharmacies and parapharmacies.
Equazen® is a trusted global brand offering science-based nutritional solutions to support brain health and cognitive function. Equazen® products feature a unique combination of essential fatty acids (Omega 3 and Omega 6), proven in over 15 clinical studies to support learning, concentration, and healthy brain development.
Matthew Brabazon, GM of SFI Health™ EMEA commented: “We are excited to offer our science-backed Equazen® solutions to Portuguese consumers, who are becoming more proactive in supporting their cognitive needs. Our entry in Portugal is another step of our development plan to grow in the region by widening our partners network and customer base.”
Mr. Nuno Carvalho, CEO of Eqyon, added: “We believe Equazen® products will make a meaningful impact in our market, thanks to their high-quality ingredients and well-documented benefits. We are proud to bring Equazen® back to Portugal and will work closely with SFI Health™ EMEA to strengthen confidence in natural solutions among healthcare professionals and consumers."
Brain health supplements are one of the fastest growing segments in the global food supplements market: in Europe, between 2023 and 2030, the market is expected to grow at a compound annual rate of 12.5%, driven by increased awareness of cognitive and mental health.
SFI Health™ EMEA and Equazen® are present in several markets, including Spain, United Kingdom, Switzerland, Poland, Czech, Slovak, the Netherlands, the Nordics and the Baltics. The company aims at further widening Equazen® distribution to unlock the potential sales of the brand and make the most of the growing brain health supplements market.
About SFI Health™
SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.
Guided by the belief in the healing potential of natural products, SFI Health™combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.
An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.
SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.
For more information go to sfihealth.com or follow us SFI Health on LinkedIn.
About Eqyon Healthcare Solutions
Eqyon Healthcare Solutions is a customer-focused company dedicated to optimizing healthcare supply chains. By leveraging strategic partnerships and innovative solutions, we help healthcare providers, pharmacies, and institutions improve efficiency, reduce costs, and enhance patient care.
We are committed to addressing the challenges within the healthcare sector through effective, evidence-based solutions. As part of this commitment, we are excited to reintroduce Equazen® to the Portuguese market. Equazen® aligns with our mission to offer natural, scientifically-backed products that promote cognitive health and well-being. In partnership with trusted global brands like Equazen®, we expand access to high-quality, proven solutions that improve lives.
At Eqyon Healthcare Solutions, we aim to be a leading provider of efficient healthcare solutions, continuously transforming challenges into opportunities and ensuring excellence in customer care.
For more information, visit eqyon.eu and follow Eqyon Healthcare Solutions on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226258206/en/
Contacts
For more information
SFI Health™ EMEA
Elisabetta Bianchi
e-mail address: elisabetta.bianchi@sfihealth.com
Eqyon
Nuno Carvalho & CEO
e-mail address: nuno.carvalho@eqyon.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces New Assignments of Directors25.6.2025 10:07:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their chairs. Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and actions are in the best interests of global stakeholders and aligned with the company’s values. This robust corporate governance model has been, and will continue to be, critical to Takeda's success. Details of the new assignments are as follows: 1. New Assignment of Directors Who Are Not Audit and Supervis
Anew Climate and Aurora Sustainable Lands Collaborate with Microsoft to Deliver Landmark 10-Year Agreement for Carbon Removal Credits25.6.2025 10:00:00 EEST | Press release
Anew Climate and Aurora Sustainable Lands today announced a 10-year agreement with Microsoft to deliver 4.8 million nature-based carbon removal credits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625732509/en/ The deal supports one of the largest permanent working forest carbon removal efforts in the United States, and will provide investments and jobs across timberland communities. The projects, developed by Anew Climate and owned and managed by Aurora Sustainable Lands, span ecologically diverse forestlands in New York, Virginia, West Virginia, Kentucky, and Florida and utilize Improved Forest Management (IFM) to generate nature-based removal credits. Removals from these projects will be among the first issued under ACR’s IFM v2.1 protocol, a next-generation methodology that advances the field via dynamic baselines, enhanced additionality and monitoring requirements, improved quantification accuracy, and increased t
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin25.6.2025 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need.1-3,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch – the main symptom of CPUO – and inflammation and fibrosis, which are hallmarks of SSc.1,3,4 “Investigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these sever
MSCI Announces Results of the MSCI 2025 Market Classification Review25.6.2025 00:55:00 EEST | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today the results of the MSCI 2025 Market Classification Review. Select highlights of this year’s review includes MSCI: Extending the consultation on a potential reclassification of Bulgaria from Standalone to Frontier Market status Continuing to monitor the implementation and market adoption of measures to enhance the accessibility of the Korean equity market, to determine whether these measures have replicated the outcomes of fully operational offshore FX markets such as those found in Developed Markets Providing updates on the market classification status of Greece Continuing to monitor the market accessibility of the Bangladesh equity market “MSCI is committed to ensuring that our market classifications reflect the evolving realities of global accessibility and investability,” said Raman Aylur Subramanian, Head of Index R&D. “In 2025, we have see
Jørgen Vig Knudstorp Nominated to Join NIKE, Inc. Board of Directors24.6.2025 23:15:00 EEST | Press release
NIKE, Inc. (NYSE:NKE) today announced Jørgen Vig Knudstorp has been nominated for election to its Board of Directors at the Company’s 2025 annual meeting of shareholders, to be held on September 9, 2025. Mr. Knudstorp was President and Chief Executive Officer of the LEGO Group (“LEGO”) from 2004 to 2016, Executive Chair of LEGO Brand Group from 2017 to 2023 and currently serves as Deputy Chair of the LEGO Foundation. He previously held various leadership positions at LEGO from 2001 to 2004. “Jørgen’s strong global experience with brand and digital marketing, strategy, and consumer products, as well as his development and fostering of culture and values, will make him an excellent addition to our board,” said Mark Parker, Executive Chairman of NIKE, Inc. “We look forward to working with Jørgen during an exciting time for NIKE where we will unlock our next chapter of growth through innovative product and distinctive brand storytelling across an integrated marketplace.” Prior to joining L
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom